GHK-Cu vs BPC-157
GHK-Cu (glycyl-L-histidyl-L-lysine copper) and BPC-157 are both tissue repair peptides with distinct mechanisms, chemical identities, and clinical profiles. GHK-Cu is a naturally occurring copper-binding tripeptide involved in tissue remodeling, while BPC-157 is a synthetic gastric pentadecapeptide with broad cytoprotective effects.
Chemical Identity
Section titled “Chemical Identity”GHK-Cu
Section titled “GHK-Cu”GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Molecular weight: 340.38 g/mol (peptide: 263.33 g/mol; Cu: 63.55 g/mol). The histidine imidazole ring coordinates Cu²⁺ with high affinity (Kd ~10⁻¹⁷ M), forming a square planar complex that delivers copper to cellular receptors.
GHK-Cu occurs naturally in human plasma, saliva, and wound fluid, with concentrations declining from ~200 µg/mL in youth to ~80 µg/mL in aging. It functions as a copper carrier for extracellular superoxide dismutase (SOD1) and as a signaling molecule for tissue remodeling.
BPC-157
Section titled “BPC-157”BPC-157 is a synthetic 15-amino acid peptide derived from human gastric juice. Sequence: GEPPPGKPADDAGLV. Molecular weight: 1419.53 g/mol. It contains no copper-binding motifs and does not require a cofactor for activity.
Mechanism of Action
Section titled “Mechanism of Action”GHK-Cu: Copper Delivery and Gene Modulation
Section titled “GHK-Cu: Copper Delivery and Gene Modulation”GHK-Cu acts through multiple convergent pathways:
- Copper delivery: Delivers Cu²⁺ to intracellular copper-binding proteins (SOD1, ceruloplasmin, cytochrome c oxidase), restoring enzymatic function
- Gene expression modulation: Alters expression of >4,000 genes involved in tissue remodeling, including upregulation of collagen synthesis (COL1A1, COL3A1), MMP activation, and TGF-β modulation
- Antioxidant: Enhances SOD1 and catalase activity, reducing oxidative stress
- Anti-inflammatory: Modulates NF-κB signaling, reducing pro-inflammatory cytokines
- Stem cell recruitment: Promotes migration of dermal fibroblasts and keratinocytes to wound sites
- ECM remodeling: Balances collagen synthesis and degradation, reducing fibrosis and promoting organized tissue repair
BPC-157: Angiogenic and Cytoprotective
Section titled “BPC-157: Angiogenic and Cytoprotective”BPC-157’s mechanism remains incompletely characterized:
- Angiogenesis: Upregulates VEGF-R2 and eNOS, promoting neovascularization
- NO system: Activates the L-arginine/NO pathway, improving endothelial function
- GI mucosal protection: Increases prostaglandin E₂ secretion, stabilizing gastric mucosal barrier
- Fibroblast recruitment: Enhances collagen deposition at wound sites
- Glycogen synthesis: Stimulates glycogen synthesis via Akt pathway activation
- Neural protection: Neuroprotective effects in TBI and peripheral nerve injury models
Comparison Table
Section titled “Comparison Table”| Property | GHK-Cu | BPC-157 |
|---|---|---|
| Structure | Tripeptide-copper complex | Pentadecapeptide |
| Molecular weight | 340 Da | 1419 Da |
| Cofactor | Cu²⁺ (essential) | None |
| Primary mechanism | Copper delivery + gene modulation | Angiogenesis + NO pathway |
| Natural occurrence | Human plasma, wound fluid | Gastric juice protein fragment |
| Route | Topical, SC, IV | Oral, SC, IP |
| Stability | Moderate (copper-dependent) | Exceptional (acid-resistant) |
| Half-life | Minutes (plasma) | Hours (estimated) |
| Gene targets | >4,000 genes modulated | Multi-target (undefined) |
Clinical Evidence
Section titled “Clinical Evidence”GHK-Cu
Section titled “GHK-Cu”GHK-Cu has stronger clinical evidence than BPC-157:
- Wound healing: Randomized controlled trials demonstrate accelerated closure of chronic wounds, burns, and surgical incisions
- Skin aging: Improved skin density, elasticity, and photodamage repair in controlled studies
- Hair growth: Promotes hair follicle regeneration in alopecia studies
- COPD: Improved lung function in preliminary trials
- Cosmetic applications: Established use in anti-aging skincare formulations
BPC-157
Section titled “BPC-157”Clinical evidence is limited to preclinical studies and anecdotal reports:
- Animal models: Extensive preclinical data in GI ulcers, tendon healing, ligament repair, IBD, spinal cord injury
- Human studies: Small open-label studies in IBD; no large RCTs
- Regulatory status: No FDA approval; no registered clinical trials
- Athlete use: Widely used anecdotally, but no controlled human efficacy data
Topical vs Systemic Application
Section titled “Topical vs Systemic Application”GHK-Cu Topical Use
Section titled “GHK-Cu Topical Use”GHK-Cu is well-suited for topical application:
- Skin penetration: Small molecular weight allows epidermal delivery
- Concentration: 0.01–1% in cosmetic formulations
- Mechanism: Direct delivery to dermal fibroblasts and keratinocytes
- Evidence: Multiple clinical studies support topical efficacy
- Formulation: Stable in cosmetic preparations with copper sulfate
BPC-157 Systemic Use
Section titled “BPC-157 Systemic Use”BPC-157 requires systemic administration for most indications:
- Oral bioavailability: ~20–50% in animal models (exceptional for a peptide)
- GI tract: Oral delivery targets GI mucosal repair
- Systemic effects: SC or IP injection required for distant tissue effects
- Topical use: Limited data; not a primary route
Stability and Formulation
Section titled “Stability and Formulation”GHK-Cu
Section titled “GHK-Cu”- Moderate stability in solution (copper binding provides some protection)
- Sensitive to oxidation at high temperatures
- Compatible with cosmetic formulations (pH 4–7)
- Requires copper supplementation for full activity
- Shelf life: 12–24 months at room temperature (dry formulation)
BPC-157
Section titled “BPC-157”- Exceptional stability across pH ranges (1–14)
- Resistant to trypsin, chymotrypsin, and胃蛋白酶
- Stable at room temperature for extended periods
- No cofactor requirements
- Shelf life: >24 months at room temperature
Safety Profile
Section titled “Safety Profile”GHK-Cu
Section titled “GHK-Cu”- Well-tolerated topically and systemically
- No established toxicity at standard doses
- Copper homeostasis maintained at physiological doses
- Theoretical concern: excessive copper in Wilson’s disease (contraindicated)
- No reported adverse events in clinical studies
BPC-157
Section titled “BPC-157”- No established toxicity in animal studies
- No reported adverse events in human case reports
- No long-term safety data in humans
- Theoretical concern: pro-angiogenic effects (unconfirmed)
- Not recommended in active malignancy (theoretical)
When to Choose Which
Section titled “When to Choose Which”GHK-Cu may be preferred when:
- Skin aging or photodamage is the target
- Topical application is desired
- Wound healing with clinical evidence is needed
- Copper delivery to restore SOD1 function is indicated
- Cosmetic or dermatological applications are primary
BPC-157 may be preferred when:
- GI tract healing is the primary target
- Oral administration is preferred
- Musculoskeletal repair (tendon, ligament) is needed
- Preclinical data is acceptable for research context
- Exceptional stability and ease of handling are important
References
Section titled “References”- Pickart L, et al. “GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration.” Biomed Res Int 2015;2015:648108.
- Sikiric P, et al. “BPC-157 and its potential for tissue repair.” Curr Pharm Des 2018;24:4698-4703.
- Pickart L, et al. “The human tripeptide GHK-copper peptide in tissue remodeling.” J Drugs Dermatol 2013;12:734-739.
- Chang CH, et al. “Thymosin beta 4 and BPC-157 in wound healing.” J Biomed Sci 2015;22:34.
- Campisi A, et al. “GHK-Cu effects on collagen synthesis and MMP expression.” Int J Cosmet Sci 2019;41:145-153.